Laboratory Corp. of America Holdings (NYSE:LH) CFO Glenn A. Eisenberg sold 5,563 shares of the firm’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $176.75, for a total value of $983,260.25. Following the sale, the chief financial officer now directly owns 17,059 shares in the company, valued at $3,015,178.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of LH stock opened at $174.95 on Friday. Laboratory Corp. of America Holdings has a 12-month low of $119.38 and a 12-month high of $188.65. The company has a quick ratio of 1.05, a current ratio of 1.14 and a debt-to-equity ratio of 0.77. The stock has a 50-day moving average price of $169.10. The company has a market capitalization of $17.17 billion, a PE ratio of 15.88, a price-to-earnings-growth ratio of 1.84 and a beta of 1.04.

Laboratory Corp. of America (NYSE:LH) last issued its earnings results on Tuesday, April 30th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.53 by $0.09. Laboratory Corp. of America had a return on equity of 16.59% and a net margin of 8.59%. The firm had revenue of $2.79 billion for the quarter, compared to analysts’ expectations of $2.82 billion. During the same period in the previous year, the firm posted $2.78 earnings per share. The business’s revenue was down 2.0% compared to the same quarter last year. As a group, research analysts forecast that Laboratory Corp. of America Holdings will post 11.27 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of Laboratory Corp. of America by 2.6% in the first quarter. BlackRock Inc. now owns 10,029,286 shares of the medical research company’s stock worth $1,534,283,000 after purchasing an additional 257,173 shares during the last quarter. Nordea Investment Management AB increased its stake in Laboratory Corp. of America by 7.3% during the fourth quarter. Nordea Investment Management AB now owns 2,120,509 shares of the medical research company’s stock worth $267,945,000 after acquiring an additional 143,426 shares during the last quarter. FMR LLC increased its stake in Laboratory Corp. of America by 81.4% during the first quarter. FMR LLC now owns 1,596,659 shares of the medical research company’s stock worth $244,257,000 after acquiring an additional 716,703 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Laboratory Corp. of America by 2.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,460,214 shares of the medical research company’s stock worth $184,501,000 after acquiring an additional 34,797 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Laboratory Corp. of America by 8.6% during the fourth quarter. Geode Capital Management LLC now owns 1,412,093 shares of the medical research company’s stock worth $178,140,000 after acquiring an additional 111,859 shares during the last quarter. 91.45% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have commented on LH shares. Wolfe Research started coverage on Iqvia in a report on Tuesday, April 2nd. They set a “market perform” rating on the stock. UBS Group cut Advanced Disposal Services from a “buy” rating to a “neutral” rating and set a $33.00 price target on the stock. in a report on Wednesday, May 1st. They noted that the move was a valuation call. TheStreet cut Viewray from a “c-” rating to a “d” rating in a report on Friday, May 3rd. Citigroup raised their price target on Martin Marietta Materials from $239.00 to $255.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Finally, Zacks Investment Research cut G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company. Laboratory Corp. of America currently has a consensus rating of “Buy” and an average price target of $181.33.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Recommended Story: What is a stock split?

Insider Buying and Selling by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.